Pre-vaccination glucose time in range correlates with antibody response to SARS-CoV-2 vaccine in type 1 diabetes

التفاصيل البيبلوغرافية
العنوان: Pre-vaccination glucose time in range correlates with antibody response to SARS-CoV-2 vaccine in type 1 diabetes
المؤلفون: Ghadeer Alhamar, Silvia Briganti, Daria Maggi, Viola Viola, Malak Faraj, Carla Zannella, Massimiliano Galdiero, Gianluigi Franci, Clorinda Fusco, Camilla Isgrò, Giulia Leanza, Ilaria Malandrucco, Andrea Spinelli, Flavia Tramontana, Domenico Iaria, Rachele Tortoriello, Silvia Pieralice, Milena Rosati, Giuseppe Matarese, Paolo Pozzilli, Mario Galgani, Rocky Strollo
المساهمون: Alhamar, Ghadeer, Briganti, Silvia, Maggi, Daria, Viola, Viola, Faraj, Malak, Zannella, Carla, Galdiero, Massimiliano, Franci, Gianluigi, Fusco, Clorinda, Isgrò, Camilla, Leanza, Giulia, Malandrucco, Ilaria, Spinelli, Andrea, Tramontana, Flavia, Iaria, Domenico, Tortoriello, Rachele, Pieralice, Silvia, Rosati, Milena, Matarese, Giuseppe, Pozzilli, Paolo, Galgani, Mario, Strollo, Rocky
سنة النشر: 2023
مصطلحات موضوعية: glucose control, Endocrinology, Type 1 diabete, mRNA vaccine BNT162b2, Endocrinology, Diabetes and Metabolism, Biochemistry (medical), Clinical Biochemistry, SARS-CoV2, continuous glucose monitoring, neutralizing antibodies, Biochemistry
الوصف: Context Poor glucose control has been associated with increased mortality in COVID-19 patients with type 1 diabetes (T1D). Objective This work aimed to assess the effect of prevaccination glucose control on antibody response to the SARS-CoV-2 vaccine BNT162b2 in T1D. Methods We studied 26 patients with T1D scheduled to receive 2 doses, 21 days apart, of BNT162b2, followed prospectively for 6 months with regular evaluation of SARS-CoV-2 antibodies and glucose control. Immunoglobulin G (IgG) to spike glycoprotein were assessed by enzyme-linked immunosorbent assay, and serum neutralization by a live SARS-CoV-2 assay (Vero E6 cells system). Glycated hemoglobin A1c (HbA1c) and continuous glucose monitoring (CGM), including time in range (TIR) and above range (TAR), were collected. The primary exposure and outcome measures were prevaccination glucose control, and antibody response after vaccination, respectively. Results Prevaccination HbA1c was unrelated to postvaccine spike IgG (r = −0.33; P = .14). Of note, the CGM profile collected during the 2 weeks preceding BNT162b2 administration correlated with postvaccine IgG response (TIR: r = 0.75; P = .02; TAR: r = −0.81; P = .008). Patients meeting the recommended prevaccination glucose targets of TIR (≥ 70%) and TAR (≤ 25%) developed stronger neutralizing antibody titers (P < .0001 and P = .008, respectively), regardless of HbA1c. Glucose control along the study time frame was also associated with IgG response during follow-up (TIR: r = 0.93; P < .0001; TAR: r = −0.84; P < .0001). Conclusion In T1D, glucose profile during the 2 weeks preceding vaccination is associated with stronger spike antibody binding and neutralization, highlighting a role for well-controlled blood glucose in vaccination efficacy.
اللغة: English
الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::6ed04d6e104d2fefb410cd5e546318e6Test
https://hdl.handle.net/11588/913506Test
حقوق: OPEN
رقم الانضمام: edsair.doi.dedup.....6ed04d6e104d2fefb410cd5e546318e6
قاعدة البيانات: OpenAIRE